PSMAddition: A phase 3 trial to compare treatment with 177 Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS5116-TPS5116, 1p
- Subject
- Language
- ISSN
- 0732183X